MedPath

Azeliragon

Generic Name
Azeliragon
Drug Type
Small Molecule
Chemical Formula
C32H38ClN3O2
CAS Number
603148-36-3
Unique Ingredient Identifier
LPU25F15UQ

Overview

Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/02/18
Early Phase 1
Not yet recruiting
2024/12/09
Phase 1
Recruiting
2023/08/14
Phase 2
Recruiting
Cantex Pharmaceuticals
2023/04/18
Phase 2
Active, not recruiting
2023/03/29
Phase 1
Recruiting
Baptist Health South Florida
2023/03/17
Phase 1
Not yet recruiting
City of Hope Medical Center
2023/03/13
Phase 1
Recruiting
Cantex Pharmaceuticals
2022/12/02
Phase 1
Active, not recruiting
Cantex Pharmaceuticals
2022/02/25
Phase 1
Recruiting
2019/06/10
Phase 2
Terminated

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

© Copyright 2025. All Rights Reserved by MedPath